Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Max Schmauss, MD
Bezirkskrankenhaus Augsburg Klinik für Psychiatrie, Psychotherapie und Psychosomatik Dr.-Mack-Straße 1 D-86156 Augsburg, Germany
Study Chair - Michael E Thase, MD
Director, Mood and Anxiety Section; 3535 Market Street, Suite 670; Philadelphia, PA 19104-3309, United States of America
Study ChairKOL profile → - Philippe Lemmens, PhD
Pharmaneuroboost N.V. Alkerstraat 30A B-3570 Alken, Belgium
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site 201
Kelowna, British Columbia, Canada
- Site 202
Penticton, British Columbia, Canada
- Site 205
Chatham, Ontario, Canada
- Site 203
Mississauga, Ontario, Canada
- Site 204
Mississauga, Ontario, Canada
- Site 103
Glendale, California, United States
- Site 101
National City, California, United States
- Site 113
Riverside, California, United States
- Site 106
San Diego, California, United States
- Site 116
San Diego, California, United States
- Site 112
Fort Myers, Florida, United States
- Site 135
Miami, Florida, United States
- Site 108
Winter Park, Florida, United States
- Site 133
Atlanta, Georgia, United States
- Site 128
Smyrna, Georgia, United States
- Site 132
Libertyville, Illinois, United States
- Site 117
Schaumburg, Illinois, United States
- Site 110
Baltimore, Maryland, United States
- Site 109
Flowood, Mississippi, United States
- Site 115
New York, New York, United States
- Site 126
Beachwood, Ohio, United States
- Site 127
Cincinnati, Ohio, United States
- Site 124
Middleburg Heights, Ohio, United States
- Site 105
Allentown, Pennsylvania, United States
- Site 123
Media, Pennsylvania, United States
- Site 122
Philadelphia, Pennsylvania, United States
- Site 119
Austin, Texas, United States
- Site 104
Dallas, Texas, United States
- Site 102
Wichita Falls, Texas, United States
- Site 107
Kirkland, Washington, United States
- Site 134
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2011
- Primary completion
- 30 Nov 2012
- Completion
- 31 Dec 2012
- Last update posted
- 7 Apr 2022
- Registered enrollment
- 555
- Registry id
- NCT01312922
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.